Literature DB >> 27272964

Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.

Richard A Marlar1, Bernadette Clement2, Jana Gausman1.   

Abstract

When administering unfractionated heparin (UFH), therapeutic levels of anticoagulation must be achieved rapidly and maintained consistently in the therapeutic range. The basic assays for monitoring UFH therapy are the activated partial thromboplastin time (APTT) and/or the chromogenic antifactor Xa or antithrombin assays. For many laboratories, the APTT is the preferred standard of practice; however, the APTT is a surrogate marker that only estimates the heparin concentration. Many factors, including patient variation, reagents of the APTT, UFH composition, and concentration can influence the APTT result. This article reviews various methods to determine the heparin therapeutic range and presents recommendations for the laboratory to establish an APTT heparin therapeutic range for all sizes of hospitals. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27272964     DOI: 10.1055/s-0036-1581128

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  12 in total

Review 1.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

2.  [Coagulation diagnostics in the clinical routine-part 2 : Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia].

Authors:  Michael Metze; Martin Platz; Christian Pfrepper; Sirak Petros
Journal:  Inn Med (Heidelb)       Date:  2022-05-19

Review 3.  Viscoelastic Testing in Pediatric Mechanical Circulatory Support.

Authors:  Katherine Regling; Arun Saini; Katherine Cashen
Journal:  Front Med (Lausanne)       Date:  2022-05-06

4.  From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.

Authors:  Jori E May; Rance Chad Siniard; Laura J Taylor; Marisa B Marques; Radhika Gangaraju
Journal:  Am J Clin Pathol       Date:  2022-03-03       Impact factor: 5.400

5.  Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing.

Authors:  James W Schurr; Anne-Marie Muske; Craig A Stevens; Sarah E Culbreth; Katelyn W Sylvester; Jean M Connors
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

6.  Individual variation in unfractionated heparin dosing after pediatric cardiac surgery.

Authors:  Keiko Hikino; Masaru Koido; Kentaro Ide; Nao Nishimura; Chikashi Terao; Taisei Mushiroda; Satoshi Nakagawa
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

7.  Heparinized swine models for better surgical/endoscopic training.

Authors:  Yuto Kubo; Kotaro Yamashita; Takuro Saito; Koji Tanaka; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Hidetoshi Eguchi; Yuichiro Doki; Kiyokazu Nakajima
Journal:  DEN open       Date:  2021-10-25

8.  An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation.

Authors:  Yuan Teng; Shujie Yan; Gang Liu; Song Lou; Yang Zhang; Bingyang Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-29

9.  Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.

Authors:  Mouhamed Djahoum Moussa; Jérôme Soquet; Antoine Lamer; Julien Labreuche; Guillaume Gantois; Annabelle Dupont; Osama Abou-Arab; Natacha Rousse; Vincent Liu; Caroline Brandt; Valentin Foulon; Guillaume Leroy; Guillaume Schurtz; Emmanuel Jeanpierre; Alain Duhamel; Sophie Susen; André Vincentelli; Emmanuel Robin
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

10.  Performance of 6 routine coagulation assays on the new Roche Cobas t711 analyzer.

Authors:  Marlies Oostendorp; Roefke L Noorman; J Dinant Nijenhuis; Jacques B de Kok
Journal:  Pract Lab Med       Date:  2019-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.